Nghiên cứu quan sát

Evaluating PCSK9 Inhibitor Effects on Outcomes in ASCVD Patients Without Prior Ischemic Events: Real-World Insights

This observational study shows PCSK9 inhibitor monoclonal antibodies significantly reduce ischaemic events and mortality over five years in patients with ASCVD but no prior ischemic events, highlighting their preventive potential in routine